S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
How will EU ban and West's price cap on Russian diesel work?
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.40
-0.06 (-2.44%)
(As of 02/3/2023 09:04 PM ET)
Add
Compare
Today's Range
$2.40
▼
$2.46
50-Day Range
$1.97
▼
$2.66
52-Week Range
$1.95
▼
$3.18
Volume
28,500 shs
Average Volume
39,596 shs
Market Capitalization
$117.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

MediciNova MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$15,870 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.20) to ($0.37) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.04 out of 5 stars

Medical Sector

1014th out of 1,025 stocks

Pharmaceutical Preparations Industry

490th out of 498 stocks

See Top Rated MarketRank™ Stocks Here
MNOV stock logo

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

January 30, 2023 | finance.yahoo.com
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
January 12, 2023 | finance.yahoo.com
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
February 6, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
January 11, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
January 9, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
January 5, 2023 | finance.yahoo.com
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
December 6, 2022 | finance.yahoo.com
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
December 5, 2022 | finance.yahoo.com
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
February 6, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
November 18, 2022 | finance.yahoo.com
MNOV: Well Financed to Get Through Tough Market Conditions…
October 13, 2022 | finance.yahoo.com
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
October 6, 2022 | reuters.com
MNOV.A - MediciNova, Inc. | Stock Price & Latest News | Reuters
September 29, 2022 | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com
September 16, 2022 | seekingalpha.com
MediciNova to get US patent for MN-166 to treat brain cancer - Seeking Alpha
September 15, 2022 | globenewswire.com
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire
September 15, 2022 | finance.yahoo.com
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
September 15, 2022 | globenewswire.com
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswire
September 14, 2022 | nasdaq.com
Health Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - Nasdaq
September 14, 2022 | finance.yahoo.com
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
September 14, 2022 | seekingalpha.com
MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders
September 14, 2022 | finance.yahoo.com
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
September 14, 2022 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada - Yahoo Finance
September 13, 2022 | globenewswire.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada - GlobeNewswire
September 13, 2022 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
August 24, 2022 | bizjournals.com
Braustin Homes appoints new executives amid a boom in business - San Antonio Business Journal - The Business Journals
August 23, 2022 | finance.yahoo.com
Global Recurrent Glioblastoma Pipeline Insight | Clinical Trials Research Report 2022 by DelveInsight - Yahoo Finance
August 19, 2022 | benzinga.com
Phase 2 Trial of MN-001 in Patients with NAFLD, Type 2 Diabetes, and Hypertriglyceridemia Underway
See More Headlines
Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings
11/10/2022
Today
2/05/2023
Next Earnings (Estimated)
2/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNOV
CUSIP
N/A
CIK
1226616
Web
medicinova.com
Phone
(858) 373-1500
Fax
858-404-0048
Employees
11
Year Founded
2000

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-10,130,000.00
Net Margins
N/A
Pretax Margin
-2,628,577.25%
Return on Equity
-16.76%
Return on Assets
-15.88%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.74
Quick Ratio
11.74

Sales & Book Value

Annual Sales
$4.04 million
Price / Sales
29.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.71 per share
Price / Book
1.40

Miscellaneous

Outstanding Shares
49,050,000
Free Float
40,855,000
Market Cap
$117.72 million
Optionable
Optionable
Beta
0.91

Social Links


Key Executives

  • Yuichi Iwaki
    President, Chief Executive Officer & Director
  • Jason Kruger
    Chief Financial Officer
  • Kazuko Matsuda
    Director & Chief Medical Officer
  • Geoffrey G. O'Brien
    Vice President & Executive Officer
  • David H. Crean
    Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.

How have MNOV shares performed in 2023?

MediciNova's stock was trading at $2.05 at the start of the year. Since then, MNOV shares have increased by 17.1% and is now trading at $2.40.
View the best growth stocks for 2023 here.

When is MediciNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our MNOV earnings forecast.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings data on Thursday, November, 10th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02.

What other stocks do shareholders of MediciNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

Who are MediciNova's major shareholders?

MediciNova's stock is owned by a variety of institutional and retail investors. Top institutional investors include Capricorn Fund Managers Ltd (0.14%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends.

How do I buy shares of MediciNova?

Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $2.40.

How much money does MediciNova make?

MediciNova (NASDAQ:MNOV) has a market capitalization of $117.72 million and generates $4.04 million in revenue each year.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 2/6/2023 by MarketBeat.com Staff